Comparison · NCT04467840-sae
Opaganib vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Opaganib vs Placebo: serious adverse events. Trial comparisons, record NCT04467840-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04467840-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.226 | 0.177 | 0.284 | wilson | |
| Risk in group 2 | 0.223 | 0.174 | 0.281 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00291 | -0.073 | 0.0789 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.01 | 0.722 | 1.42 | log | |
| Odds ratio, group 1 over group 2 | 1.02 | 0.657 | 1.57 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Opaganib than on Placebo | 344 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Opaganib | Standard of care + opaganib, 2 x 250 mg oral capsules (500 mg), every 12 hours, for 14 days (Day 1 to Day 14). | 52 | 230 | EG000 |
| Group 2 | Placebo | Standard of care + matching placebo, 2 x 250 mg oral capsules (500 mg), every 12 hours, for 14 days (Day 1 to Day 14). | 52 | 233 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse events were reported from first study drug dose (Day 1) until 4 weeks follow-up after the end of treatment, up to 42 days
Source ClinicalTrials.gov
Trial
- Title
- Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia
- NCT number
- NCT04467840
- Phases
- PHASE2, PHASE3
- Conditions
- COVID-19, Lung Infection
- Interventions
- Opaganib, Placebo
- Lead sponsor
- RedHill Biopharma Limited
- Results first posted
- 2023-10-19
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04467840?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04467840-sae